XNAS
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -4.07 | -2.46 | +39.56% | $0 | ✅ Beat | +7.46% | +18.09% | — |
| 2026-03-30 | Q4 2025 | -1.58 | -1.48 | +6.33% | $0 | ✅ Beat | -0.10% | -2.48% | -5.89% |
Showing last 2 quarters.